Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children

BMC Pediatrics

Table 4 Serum and urinary FGF23, IGFBP-7 and CysC levels grouped according to AKI status

Biomarker	Non-AKI	Mild AKI	Severe AKI	P
Biomarker	(n = 123)	(n = 10)	(n = 11)	P
sFGF23, pg/mL	79.33 [49.88–115.84]	59.97 [50.25–81.57]	92.33 [49.98–107.50]	0.372
sIGFBP-7, ng/mL	107.92 [87.47–125.02]	108.17 [83.65–135.71]	125.26 [103.07–148.35]	0.255
sCysC, mg/L	0.60 [0.47–0.78]	0.73 [0.54–0.96]	1.10 [1.06–1.72]*^#	< 0.001
uFGF23, pg/mg uCr	74.40 [39.20–225.8]	47.14 [28.82–130.6]	172.93 [114.37–448.25]*^#	0.033
uIGFBP-7, ng/mg uCr	291.57 [135.60–539.04]	244.33 [87.51–478.73]	653.50 [301.94–2072.06]*^#	0.005
uCysC, ng/mg uCr	183.17 [94.62–494.96]	122.38 [80.27–332.97]	6559.79 [1224.42–30,414.64]*^#	< 0.001

Values are median [interquartile range]
AKI network stage 1 was defined as mild AKI, and AKIN stages 2 and 3 were defined as severe AKI
*P < 0.05, compared with non-AKI; ^#P < 0.05, compared with mild AKI

ISSN: 1471-2431